Pashankar Dinesh S, Loening-Baucke Vera, Bishop Warren P
Division of Gastroenterology, Department of Pediatrics, University of Iowa, Iowa City 52242, USA.
Arch Pediatr Adolesc Med. 2003 Jul;157(7):661-4. doi: 10.1001/archpedi.157.7.661.
To assess the clinical and biochemical safety profile of long-term polyethylene glycol 3350 (PEG) therapy in children with chronic constipation and to assess pediatric patient acceptance of PEG therapy.
Prospective observational study.
Pediatric clinics at a referral center. Patients Eighty-three children (44 with chronic constipation, 39 with constipation and encopresis) receiving PEG therapy for more than 3 months.
Clinical adverse effects related to PEG therapy and acceptance and compliance with PEG therapy. Serum electrolyte levels, osmolality, albumin levels, and liver and renal function test results were measured.
At the time of evaluation, the mean duration of PEG therapy was 8.7 months, and the mean PEG dose was 0.75 g/kg daily. There were no major clinical adverse effects. All blood test results were normal, except for transient minimal alanine aminotransferase elevation unrelated to therapy in 9 patients. All children preferred PEG to previously used laxatives, and daily compliance was measured as good in 90% of children.
Long-term PEG therapy is safe and is well accepted by children with chronic constipation with and without encopresis.
评估长期聚乙二醇3350（PEG）治疗对慢性便秘儿童的临床和生化安全性，并评估儿科患者对PEG治疗的接受程度。
前瞻性观察研究。
一家转诊中心的儿科诊所。患者83名接受PEG治疗超过3个月的儿童（44名慢性便秘患儿，39名便秘合并大便失禁患儿）。
与PEG治疗相关的临床不良反应以及对PEG治疗的接受程度和依从性。检测血清电解质水平、渗透压、白蛋白水平以及肝肾功能测试结果。
在评估时，PEG治疗的平均持续时间为8.7个月，PEG的平均剂量为每日0.75 g/kg。未出现重大临床不良反应。除9名患者出现与治疗无关的短暂轻度丙氨酸转氨酶升高外，所有血液检测结果均正常。所有儿童相较于之前使用的泻药更喜欢PEG，90%的儿童每日依从性良好。
长期PEG治疗是安全的，且被患有或未患有大便失禁的慢性便秘儿童所接受。
